Skip to main content
. 2015 Jun 25;6(20):17958–17967. doi: 10.18632/oncotarget.4641

Figure 5. Circulating Th17 and Th22 cells of stage III, stage I+II MM patients and healthy controls.

Figure 5

(A) Circulating Th17 cells remained significantly higher in stage III patients compared with that in stage I+II patients or healthy controls. (B) Circulating percentages of Th22 cells were significantly higher in stage III patients compared with stage I+II patients and healthy controls.

HHS Vulnerability Disclosure